AMLN Amylin Pharmaceuticals, Inc. (MM)

SAN DIEGO, Aug. 31 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) will be presenting at the BioCentury NewsMakers Conference on Thursday, September 6, 2007 at 2:30 p.m. ET in New York, at the Thomas Weisel Healthcare Conference on Friday, September 7, 2007 at 9:10 a.m. ET in Boston and at the Bear Stearns Healthcare Conference on Monday, September 10, 2007 at 9:00 a.m. ET in New York. Daniel M. Bradbury, President and Chief Executive Officer of Amylin Pharmaceuticals, will be providing a corporate overview at BioCentury NewsMakers and Thomas Weisel. Mark G. Foletta, Senior Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, will be providing a corporate overview at Bear Stearns. The live presentations and breakout sessions will be webcast, and recordings will be made available following the events. The webcasts and recordings will be accessible through Amylin's corporate website, located at http://www.amylin.com/. To access the live webcasts, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software. About Amylin Pharmaceuticals Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Diego, California with over 1,700 employees nationwide. Further information on Amylin Pharmaceuticals and its pipeline in metabolism is available at http://www.amylin.com/. DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Alice Bahner Izzo, Executive Director, Corporate Affairs of Amylin Pharmaceuticals, Inc., +1-858-552-2200, ext. 7272 Web site: http://www.amylin.com/

Copyright